FOLH1 and hepatocellular carcinoma: All studies evaluating PSMA radioligand PET/CT in HCC reported a good performance in assessing the presence of pathological findings in liver and lymph-nodes, representing a potential novel imaging modality for patients with HCC, especially for extrahepatic disease detection [64,65,66,67,68].